From 2013: Amarantus Appoints Dr. Colin Bier to Advisory

New Post Public Reply Private Reply Replies (0) Message Board
All Aboard Bornet #27660
726
From 2013:

Amarantus Appoints Dr. Colin Bier to Advisory Board for LymPro Commercialization

SUNNYVALE, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced the appointment of Dr. Colin Bier to its Corporate Advisory Board to assist in the commercialization of the LymPro Test® as an aid in the diagnosis of the Alzheimer's type. Dr. Bier brings over 35 years of clinical expertise to the Company, having participated in numerous clinical trials, including trials in Alzheimer's disease as well as having been associated with the commercialization of several diagnostic tests.

"Dr. Bier brings significant expertise to the Company in the commercialization of diagnostic tests both through CLIA and through the FDA," said Gerald E. Commissiong, President & CEO of Amarantus. "Dr. Bier is one of the few people who has experience at the FDA concerning the intricacies of bringing a diagnostic test to market for Alzheimer's disease. We believe this regulatory experience will be highly valuable as we navigate the regulatory landscape and seek to bring LymPro to the broader physician-patient community."

Dr. Bier is managing and scientific director of ABA BioResearch, an independent bioregulatory consulting company providing expertise for technology assessment, fairness evaluation, due diligence and technical representation. Dr. Bier has extensive regulatory experience in the strategic management and development of pharmaceuticals, biopharmaceuticals, medical devices and diagnostics. Dr. Bier received his doctorate in experimental pathology from Colorado State University in 1978 and then pursued additional training as a Medical Research Council Postdoctoral Fellow and the Dr. Douglas James Fellow in the Department of Pathology, McGill University. Dr. Bier has extensive management experience in the biomedical sector having held senior scientific and executive management positions in the contract research industry as well as private industry and is a Senior Advisor to several venture funds and global biopharmaceutical companies. Dr. Bier is Chairman of the Advisory Committee for Technology Transfer of the Jewish General Hospital in Montreal, is on the scientific advisory board of three companies and serves as a director of two private companies and is a member of the Board of Trustees of Mount Sinai Hospital in Montreal, Canada. Dr. Bier will be working closely with Dr. Adam Simon, current member of the Company's Corporate Advisory Board, to finalize and implement the Company's commercialization strategy for LymPro to both maximize potential revenue and position LymPro as a potential companion diagnostic for therapeutic Alzheimer's programs.

"I am delighted to join Amarantus at a time when the Company is preparing for the introduction of this highly specific and sensitive diagnostic assay for Alzheimer's disease into the marketplace. Market launch of diagnostic products requires significant strategy in regards to initial commercial sales, regulatory matters, reimbursement and other important considerations. I am looking forward to helping the team at Amarantus make value-building decisions for both the short-term and long-term success of LymPro commercial launch and ultimate regulatory approval for widespread use."

AD represents approximately 10% of overall healthcare spend in the US, a penetration that is expected to deepen as an aging population and improved medicine leads to increased diagnoses. Healthcare spending in the US ranks higher than that of any other country, spending roughly $2 trillion, or 18% of GDP, on healthcare. In 2012, 15.4 million caregivers provided an estimated 17.5 billion hours of unpaid care, valued at more than $216 billion beyond the actual healthcare expenses. AD represents a large portion of this capital expenditure. It is estimated that the cost of caring for people with AD and other dementia's will rocket northwards from an estimated $203 billion in 2013 to a projected $1.2 trillion per year by 2050, with Medicare covering approximately 70% of costs.

The Company has estimated that peak sales for LymPro will exceed $500 million. On June 13, 2013 , the Company entered into a Laboratory Services Agreement with Becton Dickinson for the development of LymPro using BD Biosciences Custom Technology Team, and LymPro development remains on track to initiate a pivotal clinical study in early 2014 to support commercial launch of LymPro as a Laboratory-Developed Test ("LDT" under the Clinical Laboratory Improvements Act ("CLIA" in the second half of 2014. For more information on LymPro, please read the whitepaper posted on the home page of the Company's website.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 91

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Lives with Sober.Buzz: Embrace the $BUZZ Journey

Updated Category News Views 568

Welcome to Sober.Buzz and the Journey of Transformation Sober.Buzz introduces the Sober Token, known for its symbol $BUZZ, representing a promising initiative aimed at creating a supportive and empowering global community for individuals in recovery from addiction. Designed by those who understand the struggles, the project offers hope and encouragement for those seeking...

Continue Reading
Revolutionizing Ecommerce with Artifi's AI Product Setup Tool

Updated Category News Views 188

Introduction to Artifi's New AI Feature Artifi, a dynamic player in SaaS solutions for product customization, has announced a groundbreaking new feature known as AI Automated Product Setup. This innovative tool aims to drastically reduce setup times, allowing suppliers to efficiently prepare their product data for ecommerce platforms. Understanding the Setup Process The...

Continue Reading
Cleeng Pro: Revolutionizing D2C Subscription Management Today

Updated Category News Views 180

Cleeng Pro: An Innovative Platform for D2C Subscriptions Cleeng, a leader in Subscriber Retention Management, has recently introduced Cleeng Pro, a groundbreaking direct-to-consumer (D2C) subscription platform. This platform empowers creators, developers, and entrepreneurs to establish their subscription services with remarkable efficiency, all without any cost for their...

Continue Reading
SciBase's Nevisense Device Sold to NIH: A New Era in Dermatology

Updated Category News Views 255

SciBase Holding AB hit the headlines back in 2024 when it announced the sale of its flagship device, Nevisense, to the National Institutes of Health (NIH). Traders were buzzing, not just because SciBase is known for its cutting-edge dermatology tech, but because this sale signaled a massive leap into uncharted territory regarding skin health. The NIH isn't just any buyer;...

Continue Reading
FLUENT Launches Innovative MOODS Black in the Sunshine State

Updated Category News Views 262

FLUENT Launches Innovative MOODS Black in the Sunshine State FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF), a leading national cannabis company, is thrilled to announce the exciting launch of its latest product, MOODS Black. This new addition to the well-regarded MOODS lineup showcases high-potency cannabis oil infused with cannabis-derived terpenes, ensuring a superior and...

Continue Reading